191399-35-6Relevant articles and documents
Improved synthesis of C4α- and C4β-methyl analogues of 2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylate
Henry, Steven S.,Brady, Molly D.,Laird, Dana L. T.,Ruble, J. Craig,Varie, David L.,Monn, James A.
supporting information; experimental part, p. 2662 - 2665 (2012/07/27)
An efficient and divergent synthesis of C4α- and C4β-methyl- substituted analogues of 2-aminobicyclo[3.1.0]hexane 2,6-dicarboxylate, which are important tools in the study of metabotropic glutamate receptor function, has been achieved. By taking advantage
Simple conversion of fully protected amino acids to zwitterions
Hao, Junliang,Reinhard, Matt,Henry, Steven S.,Seest, Eric P.,Belvo, Matthew D.,Monn, James A.
experimental part, p. 1433 - 1434 (2012/04/10)
An operationally simple and efficient method under mild acidic conditions was developed to convert fully protected amino acids to the corresponding zwitterions without either isoelectric precipitation or ion exchange chromatography.
Methyl substitution of 2-aminobicyclo[3.1.0]hexane 2,6-dicarboxylate (LY354740) determines functional activity at metabotropic glutamate receptors: Identification of a subtype selective mGlu2 receptor agonist
Dominguez, Carmen,Prieto, Lourdes,Valli, Matthew J.,Massey, Steven M.,Bures, Mark,Wright, Rebecca A.,Johnson, Bryan G.,Andis, Sherri L.,Kingston, Ann,Schoepp, Darryle D.,Monn, James A.
, p. 3605 - 3612 (2007/10/03)
LY354740 (1) is a highly potent and selective agonist of metabotropic glutamate (mGlu) receptors 2 and 3. In the present study, we have prepared C3- and C4-methyl-substituted variants of rac-1, compounds 5, 9, and 13. Each of these racemic methyl-substituted analogues displaced specific binding of the mGlu2/3 receptor antagonist 3H-2S-2-amino-2-(1S,2S-2- carboxycycloprop-l-yl)-3-(xanth-9-yl)propanoic acid (3H-LY341495) from membranes expressing mGlu2 or mGlu3 receptor subtypes. Evaluation of the functional effects of this series on second messenger responses in cells expressing human mGlu2 or mGlu3 receptors revealed C3β-methyl analogue 5 to possess antagonist properties at both mGlu2 and mGlu3 receptors while C4β-methyl analogue 9 acts as a full agonist at each of these targets. Unexpectedly, we found that incorporation of a methyl substituent at the C4α-position as in analogue 13 results in a mixed mGlu2 agonist/mGlu3 antagonist pharmacological profile. All of the mGlu2 agonist and mGlu3 antagonist activity of rac-13 was found to reside in its resolved (+)-isomer.
